myok-8k_20200511.htm
false 0001552451 0001552451 2020-05-11 2020-05-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2020

 

MYOKARDIA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-37609

 

44-5500552

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

1000 Sierra Point Parkway

Brisbane, CA 94005

(Address of principal executive offices, including zip code)

(650) 741-0900

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001

 

MYOK

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 


 

Item 8.01 Other Items

On May 11, 2020, MyoKardia, Inc. issued a press release titled “MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy” and presented topline data from the Phase 3 EXPLORER clinical trial on a conference call and webcast. Copies of the press release and presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit

No.

 

Description

 

 

 

99.1

 

Press Release, dated May 11, 2020.

 

 

 

99.2

 

May 11, 2020 Presentation on EXPLORER-HCM Topline Data.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

MyoKardia, Inc.

 

 

 

 

 

 

 

Date: May 11, 2020

 

 

 

By:

 

/s/ Taylor Harris

 

 

 

 

 

 

Taylor Harris

 

 

 

 

 

 

Chief Financial Officer
(principal financial officer)

 

 

 

myok-ex991_35.htm

 

 

Exhibit 99.1

News Release

 

 

MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of
Obstructive Hypertrophic Cardiomyopathy

 

Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient
Observed vs. Placebo

 

Mavacamten Well Tolerated; Safety Results Comparable to Placebo

 

U.S. Regulatory Submission Planned for Early 2021

 

MyoKardia to Host Conference Call at 8:00 a.m. ET

 

Brisbane, Calif., May 11, 2020 -- MyoKardia, Inc. (Nasdaq: MYOK) today announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) (clinicaltrials.gov NCT03470545).  Mavacamten demonstrated a robust treatment effect:  the primary and all secondary endpoints of the EXPLORER trial were met with statistical significance (p≤0.0006 for all endpoints). Mavacamten was well tolerated, and meaningful improvements in symptoms, functional status and quality of life, as well as reduction or elimination in obstruction of the left ventricle, were observed among patients on treatment versus placebo.

 

“The extraordinary data from the EXPLORER pivotal trial confirm mavacamten’s ability to relieve dynamic outflow obstruction, control symptoms and improve quality of life in patients with hypertrophic cardiomyopathy," said Iacopo Olivotto, M.D., Careggi University Hospital and lead clinical investigator for the EXPLORER-HCM clinical trial. "HCM is the most common inherited cardiovascular disease, and patients face an uncertain journey that all too frequently includes debilitating symptoms, as well as serious complications, such as heart failure, stroke and cardiac arrest.  Mavacamten is the first drug developed to target the specific molecular defect of the disease.  EXPLORER represents a major achievement toward a precision-medicine approach in cardiomyopathies and should provide great hope to a community painfully aware of the lack of disease-specific treatment options.”

 

The 30-week treatment with mavacamten resulted in a highly statistically significant outcome relative to placebo (p=0.0005) for the primary endpoint in the EXPLORER-HCM trial, a composite functional analysis designed to capture the treatment effect of mavacamten relative to placebo on both symptoms and cardiac function.  

 

All secondary endpoints also demonstrated statistically significant and clinically meaningful improvements for mavacamten as compared to placebo.  Secondary endpoints in the EXPLORER-HCM trial evaluated improvements in post-exercise left ventricular outflow tract (LVOT) peak gradient (p<0.0001), New York Heart Association (NYHA) functional classification (p<0.0001), peak VO2 (p=0.0006), the Kansas City Cardiomyopathy Clinical Summary Score (KCCQ-CSS) (p<0.0001), and the HCM Symptom Questionnaire Shortness of Breath Domain Score (p<0.0001).

 

Mavacamten was well tolerated and demonstrated safety results comparable to placebo, with no new findings observed. Ninety-eight percent of patients enrolled completed the study.  Of the two percent who dropped out, none were due to reduced ejection fraction or symptoms of heart failure.  Overall rates of adverse events, serious adverse events, and cardiac adverse events, including atrial fibrillation, were comparable for patients treated with mavacamten and placebo.

 

“The resoundingly positive data from EXPLORER bring us a significant step closer to improving the lives of people with serious cardiovascular conditions, starting with HCM, a debilitating disease estimated to

 

Driven by the Heart

1000 Sierra Point Parkway, Brisbane, CA 94005 / +1 650 741 0900 / myokardia.com

 


 

affect one in every 500 people,” said Tassos Gianakakos, Chief Executive Officer of MyoKardia.  “The activity and tolerability profile observed for mavacamten in this pivotal study underscores the profound impact and potential for therapeutics that target the underlying biology of disease.  We look forward to the submission of MyoKardia’s first New Drug Application and, importantly, to serving the many patients that stand to benefit from mavacamten.  

 

The EXPLORER-HCM clinical trial is part of MyoKardia’s pivotal program studying mavacamten as a treatment for symptomatic, obstructive hypertrophic cardiomyopathy.  MyoKardia plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) in the first quarter of 2021. Results from the Phase 3 EXPLORER-HCM clinical trial will be submitted to a future professional meeting in 2020.

 

Investor and Analyst Conference Call and Live Webcast

MyoKardia management will host a conference call and webcast today beginning at 8:00 am. ET/5:00 AM PT to discuss the EXPLORER results.  Investors and analysts may access the call by dialing +1 (844) 494-0193 (domestic) or (508) 637-5584 (international) and referencing the conference ID 6270668. A live webcast of the conference call will be available on Investor section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast, and accompanying slides, will be available on the MyoKardia website for 90 days following the call.

 

About EXPLORER-HCM

The EXPLORER-HCM Phase 3 trial enrolled a total of 251 patients with symptomatic (NYHA Class II or III), obstructive hypertrophic cardiomyopathy.  All participants had measurable LVOT gradient (resting and/or provoked) ≥50 mmHg at baseline.  Patients were randomized on a 1:1 basis to receive individualized once-daily dosing of mavacamten or placebo.  Patients started on a dose of 5mg, with up to two opportunities for dose adjustments (2.5mg – 15mg) based on a combination of residual LVOT gradient, drug plasma concentration and left ventricular ejection fraction (LVEF) levels.  

 

The primary endpoint for EXPLORER-HCM was a composite functional analysis designed to capture mavacamten’s effect on both symptoms and function.  The composite functional endpoint is defined by either (1) the achievement of a ≥1.5mL/kg/min improvement in peak VO2 accompanied by an improvement of ≥1 NYHA functional class, or (2) the achievement of a ≥3.0mL/kg/min improvement of peak VO2 with no worsening in NYHA functional class.  In addition to the endpoints reported today, the EXPLORER-HCM study also assessed mavacamten’s effect on patient-reported outcomes, health-related quality of life and symptom severity assessments, changes from baseline to Week 30 in echocardiographic indices, circulating biomarkers, cardiac rhythm patterns and accelerometry.  

 

About HCM

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction.  HCM is estimated to affect one in every 500 people. The most frequent cause of HCM is mutations in the heart muscle proteins of the sarcomere. In approximately two-thirds of HCM patients, the path followed by blood exiting the heart, known as the left ventricular outflow tract (LVOT), becomes obstructed by the enlarged and diseased muscle, restricting the flow of blood from the heart to the rest of the body (obstructive HCM).  In other patients, the thickened heart muscle does not block the LVOT, and their disease is driven by diastolic impairment due to the enlarged and stiffened heart muscle (non-obstructive HCM).  In either obstructive or non-obstructive HCM patients, exertion can result in fatigue or shortness of breath, interfering with a patient’s ability to participate in activities of daily living.  HCM has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

 

About Mavacamten (MYK-461)

An investigational, novel, oral, allosteric modulator of cardiac myosin, mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.  In clinical and preclinical studies, mavacamten has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility and increased diastolic compliance.  MyoKardia is developing mavacamten for the treatment

 


 

of conditions in which excessive cardiac contractility and impaired diastolic filling of the heart are the underlying cause.  Mavacamten is initially being developed for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).  Based on its mechanism of action and evidence of therapeutic activity, mavacamten is also being studied in the clinic for the treatment of symptomatic non-obstructive HCM and among a targeted population of patients with heart failure with preserved ejection fraction (HFpEF).  

 

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.  

 

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

 

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, danicamtiv and MYK-224, our expectations regarding our continuation of discussions with the FDA and our plan to submit a New Drug Application for mavacamten, our presentation of results from the Phase 3 EXPLORER-HCM clinical trial  at a future professional meeting, and the timing of these events, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates and any ongoing effects of the COVID-19 pandemic, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contacts

 

Michelle Corral

Executive Director, Corporate Communications and Investor Relations

MyoKardia, Inc.

650-351-4690

ir@myokardia.com  

 

 

 

Hannah Deresiewicz (investors)

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

 

Julie Normant (media)

W2O

628-213-3754

jnormart@w2ogroup.com

 

 

###

 

myok-ex992_65.pptx.htm

Slide 1

May 11, 2020 Investor Call: EXPLORER-HCM Topline Data Supplemental Materials Exhibit 99.2

Slide 2

forward-looking statement Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, our plans to present detailed EXPLORER-HCM results at an upcoming cardiovascular medical meeting, to hold a pre-NDA meeting with the U.S. Food and Drug Administration (FDA), to submit a New Drug Application (NDA) for marketing approval of mavacamten in the U.S. and to initiate discussions with EMA and align on a registrational plan for mavacamten in Europe, and the timing of these events, as well as the requirements for registration of the Company's product candidates, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates and the effects of the ongoing COVID-19 pandemic, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. [Company Logo] 2

Slide 3

introduction Patients on treatment experienced meaningful results: Improvement of symptoms Improvement in functional status Reduction or elimination of LVOT gradient Mavacamten’s safety results were comparable to placebo Mavacamten was well tolerated; primary and all secondary endpoints were met with high statistical significance (p<0.0006) [Company logo]3

Slide 4

EXPLORER-HCM study design Multi-national, randomized, double-blind, placebo-controlled 68 clinical sites 13 countries 108 128 patients enrolled from Europe patients enrolled in the U.S. 15 patients enrolled from Israel [Company logo] 4

Slide 5

EXPLORER-HCM baseline characteristics Mavacamten (n=123) Placebo (n=128) Age, mean, years (SD) 58.5 (12.2) 58.5 (11.8) Female sex, n (%) 57 (46.3) 45 (35.2) NYHA Class, n (%) Class II 88 (71.5) 95 (74.2) Class III 35 (28.5) 33 (25.8) Peak VO2, mL/kg/min, mean (SD) 18.9 (4.9) 19.9 (4.9) NT-proBNP, pg/mL, median (Q1, Q3) 784 (373, 1759) 648 (354, 1360) Background therapy, n (%) Beta blockers 94 (76) 95 (74) Calcium channel blockers 25 (20) 17 (13) [Company logo]5

Slide 6

EXPLORER-HCM baseline echo parameters Mavacamten (n=123) Placebo (n=128) Resting LVOT gradient, mmHg, mean (SD) 51.7 (29.4) 51.1 (31.9) Valsalva LVOT gradient, mmHg, mean (SD) 72.3 (31.7) 73.9 (32.0) Post-exercise LVOT gradient, mmHg, mean (SD) 85.7 (34.3) 84.7 (35.6) LVEF, % (SD) 74.1 (5.8) 74.2 (5.9) [Company logo]6

Slide 7

EXPLORER-HCM primary and secondary objectives Secondary Efficacy Objectives Post-exercise LVOT gradient Peak VO2 NYHA Class Kansas City Cardiomyopathy Clinical Summary Score (KCCQ-CSS) Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness of Breath Questions (HCMSQ-SoB) Change from baseline to Week 30 Peak VO2 NYHA Classification Definition #1 >1.5 mL/kg/min and Reduction (i.e. improvement) of 1 or more class Definition #2 >3.0 mL/kg/min and No worsening Primary endpoint can be achieved through either Definition #1 or Definition #2 Primary efficacy objective: composite functional endpoint [Company logo]7

Slide 8

statistically significant benefits at-a-glance Mavacamten (n=123) Placebo (n=128) P-value Primary endpoint Composite functional, n (%) 45 (37%) 22 (17%) 0.0005 Secondary endpoints Post-exercise LVOT peak gradient, mmHg, mean (SD) -47.2 (40.3) -10.7 (29.6) <0.0001 Peak VO2, mL/kg/min, mean (SD) 1.4 (3.1) -0.05 (3.0) 0.0006 NYHA improved ≥ 1 Class, n (%) 80 (65%) 40 (31%) <0.0001 KCCQ-CSS, mean (SD) 13.6 (14.4) 4.2 (13.7) <0.0001 HCMSQ-SoB score, mean (SD) -2.82 (2.7) -0.85 (2.4) <0.0001 Change from baseline to week 30 KCCQ-CSS = Kansas City Cardiomyopathy Questionnaire Clinical Summary Score HCMSQ-SoB = Hypertrophic Cardiomyopathy Symptom Questionnaire – Shortness of Breath [Company logo]8

Slide 9

meaningful improvements in symptoms and functional capacity peak VO2 Peak VO2 change from baseline to week 30 (n=251) Mavacamten Placebo mL/kg/min mean (SD) 1.4 (3.1) -0.05 (3.0) p=0.0006 NYHA Class change from baseline to week 30 (n=251) Mavacamten Placebo Improvement of ≥1 classes 65% 31% % achieving Class I status 50% 21% symptoms p<0.0001 of patients on mavacamten met the composite functional endpoint vs. 17% of patients on placebo 37% [Company logo]9

Slide 10

LVOT obstruction was reduced or eliminated in a majority of patients obstruction Post-exercise LVOT peak gradient at week 30 Mavacamten Placebo Below 50mmHg (Threshold for surgery) 74% (n=101) 21% (n=106) Below 30mmHg (Diagnostic criteria for obstruction) 57% (n=113) 7% (n=113) p<0.0001 of patients on mavacamten achieved a “complete response” asymptomatic (NYHA Class I) AND obstruction reduced to below the diagnostic threshold* at Week 30 (vs. 1% of patients on placebo) 27% *LVOT gradient at rest and provoked; 30mmHg = guideline-based diagnostic threshold for obstruction [Company logo]10

Slide 11

Improvements in quality of life measures HCMSQ-SoB score change from baseline to week 30 mean (SD) Mavacamten Placebo -2.82 (2.7) -0.85 (2.4) p<0.0001 KCCQ-CSS change from baseline to week 30 mean (SD) Mavacamten Placebo 13.6 (14.4) 4.2 (13.7) p<0.0001 [Company logo]11

Slide 12

Dosing approach demonstrated favorable results in efficacy measures and was well tolerated 2% (5/251) of participants experienced a temporary discontinuation associated with reduced ejection fraction 3 patients on mavacamten and 2 on placebo Following a dose modification, all patients continued and completed the study [Company logo]12

Slide 13

251 mavacamten was well tolerated low drop out rate (2%) 3 due to adverse events (2 mavacamten, 1 placebo) 2 withdrew for other reasons (1 mavacamten, 1 placebo) no participants withdrew due to reduced EF or symptoms of heart failure serious adverse events Occurred in 10 (8.1%) participants on mavacamten vs. 11 (8.6%) on placebo Higher number of SAEs occurred on placebo (20) vs. mavacamten (12) cardiac SAEs Occurred in 4 participants on mavacamten vs. 4 participants on placebo One sudden death occurred in the placebo arm of the study atrial fibrillation Events occurred in 8 (6.5%) participants on mavacamten vs. 9 (7.0%) participants on placebo 2 participants on mavacamten (1.6%) vs. 4 participants on placebo (3.1%) experienced atrial fibrillation SAEs treatment emergent AEs TEAEs occurred in 108 (87.8%) participants on mavacamten vs. 101 (78.9%) participants on placebo [Company logo]13

Slide 14

HCM is largely caused by mutations in the sarcomere MYOFIBRIL On/active myosin Off/relaxed myosin Muscle fibers are composed of myofibrils, which in turn are composed of bundles of sarcomeres HEART MUSCLE FIBERS Actin thin filament Actin-myosin cross-bridge Myosin thick filament Force-producing myosin head Mutations in sarcomeric proteins Normal contractility Ordered sarcomeres Effective relaxation HCM SARCOMERE Hypercontractility Disordered sarcomeres Cardiac tissue stiffness Too many engaged cross-bridges NORMAL SARCOMERE [Company logo]14

Slide 15

HCM is a progressive, debilitating disease Note: All figures approximate; reflect estimated totals 1. Maron et al, Circulation 1995 | 2. Maron et al, AJC 2016 | 3. Maron et al, Circulation 2006 current treatment options are inadequate and non-specific 100K diagnosed(2) 530K Undiagnosed Increased mortality Chronic symptoms Decreased functionality Long-term complications Increasing burden 1/3 non-obstructive HCM(3) 2/3 obstructive HCM(3) Prevalence ~1/500(1) [Company logo]15

Slide 16

obstructive HCM HCM is a disease of hypercontractility that leads to hypertrophy and impaired relaxation of the left ventricle The heart is working harder, but unable to fill with sufficient blood to meet the body’s needs In obstructive HCM, the thickening of the heart’s walls may block the flow of oxygenated blood to the tissues and organs of the body Thickened heart muscle and septum Decreased left ventricular volume Enlarged left atrium LVOT obstruction [Company logo]16

Slide 17

planned next steps on path to registration Present detailed EXPLORER-HCM results at an upcoming cardiovascular medical meeting (2H 2020) Pre-NDA meeting with FDA anticipated (Q3 2020) Submit NDA for marketing approval in the US (Q1 2021) Initiate process with EMA to discuss EXPLORER-HCM study data and align on registrational plan for Europe (2H 2020) [Company logo]17

Slide 18

3 2 MYK-224 nHCM & HFpEF (diastolic) HFrEF (systolic) LUS-1 Danicamtiv* gDCM Begin with proof-of-concept validation in a targeted population Apply our precision medicine approach to adjacent patient populations Leverage learnings to the discovery of new molecules and new indications 1 2 3 Mavacamten oHCM ACT-1 changing the paradigm for pipeline growth * Formerly MYK-491 [Company logo]18

Slide 19

today Q2 2020 Platform strategy for aggressive value creation starting with mavacamten and danicamtiv Positive Phase 3 data for mavacamten in obstructive HCM Growing body of data fueling pipeline – new indications (HFpEF) AND new discoveries Global rights to entire portfolio World-class team focused on our mission and vision [Company logo]19

Slide 20

Driven by the heart